A Caltech Library Service

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

Radhakrishnan, Senthil K. and Lee, Candy S. and Young, Patrick and Beskow, Anne and Chan, Jefferson Y. and Deshaies, Raymond J. (2010) Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells. Molecular Cell, 38 (1). pp. 17-28. ISSN 1097-2765. PMCID PMC2874685.

[img] PDF - Accepted Version
See Usage Policy.

PDF - Supplemental Material
See Usage Policy.


Use this Persistent URL to link to this item:


In Saccharomyces cerevisiae, chemical or genetic inhibition of proteasome activity induces new proteasome synthesis promoted by the transcription factor RPN4. This ensures that proteasome activity is matched to demand. This transcriptional feedback loop is conserved in mammals, but its molecular basis is not understood. Here, we report that nuclear factor erythroid-derived 2-related factor 1 (Nrf1), a transcription factor of the cap “n” collar basic leucine zipper family, but not the related Nrf2, is necessary for induced proteasome gene transcription in mouse embryonic fibroblasts (MEFs). Promoter-reporter assays revealed the importance of antioxidant response elements in Nrf1-mediated upregulation of proteasome subunit genes. Nrf1^(−/−) MEFs were impaired in the recovery of proteasome activity after transient treatment with the covalent proteasome inhibitor YU101, and knockdown of Nrf1 in human cancer cells enhanced cell killing by YU101. Taken together, our results suggest that Nrf1-mediated proteasome homeostasis could be an attractive target for therapeutic intervention in cancer.

Item Type:Article
Related URLs:
URLURL TypeDescription CentralArticle
Deshaies, Raymond J.0000-0002-3671-9354
Additional Information:© 2010 Elsevier. Received 18 December 2009; revised 10 February 2010; accepted 26 February 2010. Published: April 8, 2010. Available online 8 April 2010. We thank Millenium Pharmaceuticals for their generous gifts of bortezomib and MLN4924, Mark Smythe and Craig Crews for YU101, and Mei-Ling Kuo (City of Hope) for the p19ARF shRNA construct. We thank S. Materna for help with qPCR. We are grateful to A. Varshavsky and members of the Deshaies lab for critical reading of the manuscript. S.K.R. is supported by the multidisciplinary postdoctoral award (W81XWH-07-1-0641) from the Department of Defense Breast Cancer Research Program. P.Y. is supported by the Swedish Research Council and the Swedish Cancer Society. J.Y.C. and C.S.L. are supported by grants (CA091907 and NS065223) from the National Cancer Institute and National Institute of Neurological Disorders and Stroke. R.J.D. is an HHMI Investigator, and this work was supported in part by HHMI and Weston Havens Foundation. Stemming from founder’s shares in Proteolix, R.J.D. retains rights to milestone payments from Onyx contingent upon FDA and EMEA approvals of carfilzomib.
Funding AgencyGrant Number
Department of Defense Breast Cancer Research ProgramW81XWH-07-1-0641
Swedish Research CouncilUNSPECIFIED
Swedish Cancer SocietyUNSPECIFIED
National Cancer InstituteCA091907
National Institute of Neurological Disorders and Stroke (NINDS)NS065223
Howard Hughes Medical Institute (HHMI)UNSPECIFIED
Weston Havens FoundationUNSPECIFIED
Subject Keywords:Proteins; Cellcycle
Issue or Number:1
PubMed Central ID:PMC2874685
Record Number:CaltechAUTHORS:20100610-122051580
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:18641
Deposited By: Jason Perez
Deposited On:11 Jun 2010 14:52
Last Modified:03 Oct 2019 01:45

Repository Staff Only: item control page